<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519075</url>
  </required_header>
  <id_info>
    <org_study_id>1386</org_study_id>
    <nct_id>NCT02519075</nct_id>
  </id_info>
  <brief_title>11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE</brief_title>
  <official_title>Diagnostic and Prognostic Role of 11C-Choline PET/CT and DWI MRI for Response Assessment in Patients Affected by Hepatocellular Carcinoma (HCC) and Candidate to TARE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective exploratory study specifically investigating the diagnostic and predictive role
      of 11C-Choline PET/CT and DWI MRI for response assessment in patients affected by HCC and
      candidate to TARE. A minimum number of 20 patients will be considered for the analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the study, all patients with a histological diagnosis of HCC and eligible for TARE, i.e.
      with liver predominant disease who are not eligible for curative surgery, after
      multidisciplinary discussion will be included. In all cases, patients will undergo
      11C-Choline PET/CT and DWI MRI before starting radioembolization and will be subsequently
      restaged 3 months after treatment completion. A minimum number of 20 patients will be
      considered for the analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing TARE for HCC</measure>
    <time_frame>Change from Baseline in SUVmax up to 3 months after TARE</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocarcinoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Observational study</description>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy specimen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients affected by HCC and referred to our Institution for TARE will be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a histological diagnosis of HCC and eligible for TARE, i.e. with liver
             predominant disease who are not eligible for curative surgery, after multidisciplinary
             discussion will be included;

          -  obtained informed consent

        Exclusion Criteria:

          -  patients age &lt;18 years

          -  pregnancy or breast-feeding;

          -  patients affected by other malignancies within the last 3 years;

          -  disseminated extrahepatic disease;

          -  severely abnormal excretory liver function tests or ascites suggestive of liver
             failure;

          -  hepatopulmonary shunt &gt;20%;

          -  vascular variants and abnormalities as demonstrated on pre-treatment angiography,
             which cannot be corrected by embolisation and which lead to reflux of hepatic arterial
             blood to the stomach, pancreas or bowel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egesta Lopci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Clinical and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Egesta Lopci, MD</last_name>
    <phone>+39 0282247542</phone>
    <email>egesta.lopci@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcello Rodari, MD</last_name>
    <phone>+39 0282247544</phone>
    <email>marcello.rodari@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egesta Lopci, MD</last_name>
      <phone>+39 0282247542</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lopci E, Torzilli G, Poretti D, de Neto LJ, Donadon M, Rimassa L, Lanza E, Sabongi JG, Ceriani R, Personeni N, Palmisano A, Pedicini V, Comito T, Scorsetti M, Chiti A. Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1399-407. doi: 10.1007/s00259-015-3079-5. Epub 2015 May 12.</citation>
    <PMID>25962590</PMID>
  </reference>
  <reference>
    <citation>Kirienko M, Sollini M, Lopci E, Versari A, Chiti A. Applications of PET imaging with radiolabelled choline (11C/18F-choline). Q J Nucl Med Mol Imaging. 2015 Mar;59(1):83-94. Epub 2015 Feb 12. Review.</citation>
    <PMID>25677590</PMID>
  </reference>
  <reference>
    <citation>Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, Grahek D, Montravers F, Poupon R, Rosmorduc O. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1285-9. Epub 2006 Jun 27.</citation>
    <PMID>16802155</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocarcinoma</keyword>
  <keyword>TARE</keyword>
  <keyword>response assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

